secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001641172-25-013176
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025
---------------------------------------------------------------

- Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.
- Trial evaluates THIO sequenced with CPI cemiplimab in advanced NSCLC patients after 2+ prior therapies.
- Corporate presentation posted to MAIA website on June 2, 2025, filed as Exhibit 99.2.
- Poster available on MAIA's website from June 2, 2025 onward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/0001641172-25-013176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225013176/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer